Two days ago Relief and Acer presented data of ACER-001, a supplement to battle against various inborn errors of metabolism at the Genetic Metabolic Dieticians International Conference.
Surprisingly, Acer stock didn’t go up as expected but RLFTF gained 7.35% on over 1.4 million volume. Since July 2021 Relief stock has been bleeding from $0.30 to $0.0530. Gradually, the number of holders has kept shrinking so the stock was kicked out of trending searches among penny stocks.
If ACER-001 succeeds in sales Relief may take huge credit. So the most likely stock jump will occur right away after announcing positive financial results. This week RLFTF has finally been spotted again. New buyers might jump onto this bandwagon soon.